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Abstract Sequencing studies have implicated haploinsufficiency of ARID1B, a SWI/SNF
chromatin-remodeling subunit, in short stature (Yu et al., 2015), autism spectrum disorder (O’Roak
et al., 2012), intellectual disability (Deciphering Developmental Disorders Study, 2015), and corpus
callosum agenesis (Halgren et al., 2012). In addition, ARID1B is the most common cause of Coffin-
Siris syndrome, a developmental delay syndrome characterized by some of the above abnormalities
(Santen et al., 2012; Tsurusaki et al., 2012; Wieczorek et al., 2013). We generated Arid1b
heterozygous mice, which showed social behavior impairment, altered vocalization, anxiety-like
behavior, neuroanatomical abnormalities, and growth impairment. In the brain, Arid1b
haploinsufficiency resulted in changes in the expression of SWI/SNF-regulated genes implicated in
neuropsychiatric disorders. A focus on reversible mechanisms identified Insulin-like growth factor
(IGF1) deficiency with inadequate compensation by Growth hormone-releasing hormone (GHRH)
and Growth hormone (GH), underappreciated findings in ARID1B patients. Therapeutically, GH
supplementation was able to correct growth retardation and muscle weakness. This model
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functionally validates the involvement of ARID1B in human disorders, and allows mechanistic
dissection of neurodevelopmental diseases linked to chromatin-remodeling.
DOI: 10.7554/eLife.25730.001
Introduction
It is becoming clear that SWI/SNF chromatin-remodeling complexes have a major impact on human
diseases, from cancer to neuropsychiatric disorders to body size regulation (Kadoch and Crabtree,
2015; Ronan et al., 2013). SWI/SNF chromatin-remodeling complexes use the energy of ATP to
remodel nucleosome density and position to control epigenetic states, lineage differentiation, and
cellular growth during development and cancer (Kadoch and Crabtree, 2015; Ho and Crabtree,
2010). ARID1B is a 236 kDa protein that contains an AT-rich DNA interactive domain (‘ARID’
domain) and facilitates proper genomic targeting of ARID1B containing SWI/SNF complexes.
ARID1B is the most commonly mutated gene in Coffin-Siris syndrome (CSS), a monogenic syndrome
characterized by growth retardation, facial dysmorphism, and intellectual disability (ID)
(Santen et al., 2012; Tsurusaki et al., 2012; Wieczorek et al., 2013). In addition, ARID1B is among
the most frequently mutated genes in autism spectrum disorders (ASD) and non-syndromic ID
(O’Roak et al., 2012; Deciphering Developmental Disorders Study, 2015). In these diseases,
ARID1B mutations are scattered across the gene without clear accumulation in particular domains
(Ronan et al., 2013; Santen et al., 2013). Since these are often predicted to be nonsense or frame-
shift mutations, heterozygous ARID1B loss-of-function is hypothesized to be the causative genetic
mechanism. Up to this point, if and how ARID1B mutations translate into various human phenotypes
is unknown, and animal models have not yet been used to model or devise novel treatments for
these ‘ARID1B-opathies’.
Here, we employ genetically engineered mouse models to elucidate the phenotypic impact of
Arid1b mutations. We developed an Arid1b haploinsufficient mouse that exhibits neuropsychiatric
abnormalities reminiscent of ASD, as well as the developmental and growth retardation phenotypes
seen in CSS. Although not previously considered a cardinal feature of this syndrome, a meta-analysis
of 60 patients by Santen et al. shows that on average, stature is considerably shortened in CSS
patients by about two standard deviations (Santen et al., 2013). After showing the clinical relevance
of our mouse model, we focused on potentially reversible etiologies of behavioral and growth phe-
notypes. We observed GHRH-GH-IGF1 axis deficiencies in Arid1b heterozygous mice and also found
evidence for this in humans. GH supplementation in mice rescued growth retardation and muscle
weakness, which are also salient features of human ARID1B-opathies. Though successful in Mecp2
mutant mice that model Rett syndrome (Tropea et al., 2009; Castro et al., 2014), intervening on
the GH-IGF1 axis was not able to reverse neuropsychiatric defects associated with Arid1b. Our find-
ings not only functionally validate ARID1B’s involvement in human disease, they suggest underap-
preciated clinical manifestations of human ARID1B mutations that can be approached from a
treatment-perspective.
Results
Characterization of Arid1b+/- and Arid1b-/- mice
Using Cas9 germline gene-editing, we generated whole-body knockout and conditional floxed mice
(Figure 1A). Arid1b is prominently expressed in the cortex, cerebellum, and hippocampus
(Lein et al., 2007; Ka et al., 2016) (Figure 1—figure supplement 1A). In heterozygous mice, Arid1b
mRNA transcripts were reduced in liver, whole brain, pituitary gland, dentate gyrus, and hypothala-
mus (Figure 1B). Protein levels showed a similar pattern in whole brain extracts, and homozygous P0
pups showed an absence of ARID1B protein (Figure 1C). Homozygous mice were born but died
perinatally (Figure 1D). To model the genetics of haploinsufficient human ARID1B-opathies, we gen-
erated whole-body heterozygous (Arid1b+/-) mice [birth ratios from Arid1b+/- x Arid1b+/+ crosses:
389/661 (58.9%) WT, 272/661 (41.1%) Arid1b+/-], which survived into adulthood and appeared
healthy but were small for age (Figure 1E). There were no abnormalities in electrolytes, liver function
tests, or blood counts (Figure 1—figure supplement 1B–D). 16/272 (6.6%) of Arid1b+/- mice had
hydrocephalus, the displacement of brain parenchyma by accumulated cerebrospinal fluid, a
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condition that frequently accompanies Dandy-Walker malformations seen in CSS patients
(Schrier Vergano et al., 2013) (Figure 1—figure supplement 1E).
Arid1b+/- mice developed abnormal social, vocal, and behavioral
phenotypes
Given the associations between Arid1b mutations and ASD, we examined behaviors related to this
disorder. To examine social interactions, we quantified the time spent interacting with a juvenile tar-
get mouse. Compared to WT littermate controls, Arid1b+/- mice spent significantly less time inter-
acting with unfamiliar juvenile mice (Figure 1F), suggesting impaired social behavior. To enrich the
connections between Arid1b+/- mice and ASD-like phenotypes, we also performed grooming and
marble burying tests that examined repetitive behaviors (Silverman et al., 2010). Consistent with
other ASD mouse models, Arid1b+/- mice exhibited increased self-grooming (Figure 1G) and poten-
tially as a consequence, buried less marbles (Figure 1—figure supplement 2A). A similar pattern of
repetitive behaviors was seen with Synapsin knockout mice, another mouse model of ASD
(Greco et al., 2013).
Another feature of ASD is abnormal communication and language. Several mouse models of ASD
and language disorders show alterations in one or more vocalization parameters, including the num-
ber, duration, frequency, amplitude, and other characteristics of ultrasonic vocalizations (USVs)
(Konopka and Roberts, 2016; Araujo et al., 2015). Furthermore, ASD patients who have retained
speech tend to exhibit abnormalities in voice quality and pitch (Kanner, 1968; Bonneh et al., 2011).
USVs emitted by Arid1b+/- mice are longer in duration, and have abnormal pitch (Figure 1H,I and
Figure 1—figure supplement 2B). Interestingly, Arid1b+/- mice emitted the same total number of
USVs compared to WT mice (Figure 1—figure supplement 2C), suggesting altered modulation
rather than absent vocalizations.
Anxiety-like behavior, a comorbidity of ASD, was examined using three separate tasks in male
mice. In the open field test, Arid1b+/- mice spent significantly more time in the periphery while
eLife digest DNA does not just float freely inside our cells. Instead, it is wound around proteins
called histones and packaged tidily into a form called chromatin. This packaging allows genes to be
switched on or off by making it easier or harder to access different stretches of the genetic code.
A group of proteins called the SWI/SNF chromatin-remodeling complex are responsible for the
packing and unpacking of DNA during development, dictating the fate of thousands of genes.
Mutations that affect one component of this complex, a protein known ARID1B, are associated with
a rare genetic condition called Coffin-Siris syndrome, and may also have a role to play in autism
spectrum disorders and intellectual disability. However, there were previously no animal models that
can be used to study this mutation in the laboratory.
Celen, Chuang et al. have now genetically modified mice to remove one of their two copies of
the gene that encodes the mouse equivalent of ARID1B. This change replicates the mutation that is
most commonly seen in people with Coffin-Siris syndrome. Celen, Chuang et al. report that the
mutant mice with just one working copy of the gene showed many features also seen in Coffin-Siris
syndrome, including a smaller size and weaker muscles. The mutant mice also repeated certain
behaviors, like grooming themselves, and showed unusual interactions with other mice.
Further tests showed that the mutant mice had lower than expected levels of growth hormone in
their blood. The mice were then treated with growth hormone supplements to find out if this could
reverse any of their symptoms. Indeed, this treatment made the mice larger and stronger, but did
not change their behavior.
Some doctors are already treating people with Coffin-Siris syndrome with growth hormone, and
these new findings suggest that this treatment counteracts defects caused directly by the mutation
affecting ARID1B. Moreover, this mouse model will allow the role of ARID1B to be investigated
further in the laboratory, and could be used as a tool to discover, develop and test new treatments
for Coffin-Siris syndrome.
DOI: 10.7554/eLife.25730.002
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Figure 1. Arid1b+/- mice exhibit physical manifestations of developmental delay, autistic-like features, and abnormal behavioral phenotypes. (A)
Schematic of Arid1b whole body heterozygous mice in which exon five is deleted (hereafter referred as Arid1b+/-) and Arid1b floxed mice. (B) Relative
Arid1b mRNA levels in selected organs and brain regions as assessed by qPCR. (C) Relative Arid1b levels in p0 mouse limb (top panel) and whole brain
extracts at p45 as assessed by western blot analysis. (D) Appearance of WT and Arid1b+/- mice at postnatal day 0. (E) Appearance of WT and Arid1b+/-
Figure 1 continued on next page
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avoiding the anxiety-provoking center (Figure 1J). In the elevated plus maze, Arid1b+/- mice spent
more time in the anxiety-relieving, walled arms of the maze (Figure 1K). In the dark-light box test,
Arid1b+/- mice avoided exploring the brightly lit chamber (Figure 1L). WT and mutant mice traveled
equal distances both initially and over a 2 hr time period, making locomotor differences less likely a
confounder in simple environments (Figure 1—figure supplement 2D). These tests consistently
demonstrated higher levels of anxiety-like behavior in Arid1b+/- mice compared to their WT
littermates.
Given the associations between Arid1b haploinsufficiency and intellectual disability, we assessed
cognitive functions in Arid1b+/- mice. The Morris water maze test, a contextual fear-conditioning
test, and a cued fear-conditioning test each did not reveal defects in memory and learning (Fig-
ure 1—figure supplement 2E–G). The genotypes were equally able to sense the electric shock
applied during fear conditioning (Figure 1—figure supplement 2H). Overall, these tests showed
that Arid1b+/- mice displayed abnormal social, vocal, and behavioral phenotypes, but did not clearly
have cognitive or memory deficiencies.
Arid1b haploinsufficiency resulted in neuroanatomical and gene
expression abnormalities
In an effort to understand how behavioral abnormalities arose, we examined Arid1b+/- brains for
other neurodevelopmental abnormalities. Because some patients with ARID1B mutations exhibit cor-
pus callosum hypoplasia or agenesis (Schrier Vergano et al., 2013), we examined brains of
Arid1b+/- mice and identified a significant reduction in corpus callosum volume (Figure 2A). Consis-
tent with studies showing that small hippocampus, dentate gyrus, and cortex size are associated
with anxiety and depressive disorders in mice and humans (Persson et al., 2014; Travis et al., 2015;
Boldrini et al., 2013; Schmaal et al., 2017), Arid1b+/- mice have smaller dentate gyri (Figure 2B)
and both Arid1b+/- and Arid1b-/- pups had reduced cortical thickness with reduced TBR1 marked
neuronal cellularity (Figure 2—figure supplement 1A–D). Less proliferating cells were also seen in
the subgranular zone of the dentate gyrus (Figure 2C,D,F,G), especially in posterior regions
(Figure 2E,H). Thus, reduced corpus callosum size, dentate gyrus size, cortex thickness, and prolifer-
ation are neuroanatomical and cellular correlates of the behavioral phenotypes seen in Arid1b
mutants.
RNA-seq was performed to examine the impact of Arid1b haploinsufficiency on transcriptional
output in the hippocampus. Differential gene expression analysis showed 56 significantly down- and
79 upregulated mRNAs (edgeR FDR < 0.05; Figure 3A). As expected, Arid1b was one of the most
Figure 1 continued
littermates at 1 month of age. (F) Juvenile social interaction testing for 10 WT and 9 Arid1b+/- male mice. (G) Grooming test for 10 WT and 9 Arid1b+/-
female mice. (H, I) The ultrasonic vocalization (USV) test measuring the duration and frequency of vocal communication in 63 WT and 33 Arid1b+/- male
and female mice during separation of pups from dams at postnatal day 4. (J) Representative traces of WT and Arid1b+/- mice in the open field and time
spent in the indicated areas for 20 WT and 20 Arid1b+/- 8 week old male mice. (K) Representative traces of WT and Arid1b+/- mice in the elevated plus
maze and time spent in the indicated areas for 20 WT and 20 Arid1b+/- 8 week old male mice. (L) Dark-light box testing for 20 WT and 20 Arid1b+/- 8
week old male mice. Values represent mean ± SEM. Asterisks indicate significant differences between indicated littermate genotypes, *p-value  0.05;
**p-value  0.01; ***p-value  0.001; ****p-value  0.0001; ns, not significant. Student’s t-test (two-tailed distribution, two-sample unequal variance)
was used to calculate p-values unless otherwise indicated in the figure legend.
DOI: 10.7554/eLife.25730.003
The following source data and figure supplements are available for figure 1:
Source data 1.
DOI: 10.7554/eLife.25730.004
Figure supplement 1. Additional characterization of Arid1b+/- mice.
DOI: 10.7554/eLife.25730.005
Figure supplement 1—source data 1.
DOI: 10.7554/eLife.25730.006
Figure supplement 2. Additional neurobehavioral testing on Arid1b+/- mice.
DOI: 10.7554/eLife.25730.007
Figure supplement 2—source data 1.
DOI: 10.7554/eLife.25730.008
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Figure 2. Arid1b haploinsufficiency results in neuroanatomical abnormalities implicated in neuropsychiatric diseases. (A) Relative corpus callosum
volume quantified through Cavalieri analysis (n = 8 WT and 7 Arid1b+/- brains from 50 day old females). (B) Dentate gyrus volume quantified through
Cavalieri analysis (n = 7 WT and 7 Arid1b+/- brains from 50 day old females). (C) Representative Ki67 immunostaining. (D) Quantitation of Ki67+ total
cell number (8 WT and 7 Arid1b+/- brains from 50 day old females). (E) Bregma analysis was used to determine cell proliferation (Ki67) as a function of
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calculate the statistics. (F) Representative BrdU immunostaining. WT and Arid1b+/- mice received one injection per day of the thymidine analog,
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DOI: 10.7554/eLife.25730.009
The following source data and figure supplements are available for figure 2:
Figure 2 continued on next page
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downregulated genes. Globally, differentially regulated genes were associated with nervous system
development as well as psychological, behavioral, and developmental disorders (Figure 3B).
Arid1b+/- tissues also showed specific alterations in Ephrin, nNOS, axonal guidance and glutamate
receptor signaling pathways (Figure 3C). 14 of 140 (10%) differentially regulated genes were among
the highest ranking candidate autism risk genes identified in the SFARI gene database (Basu et al.,
2009) (Figure 3D). To determine if some of these genes could be directly regulated by SWI/SNF,
we analyzed the ChIP-Seq targets of Smarca4 (Brg1), a core SWI/SNF complex subunit
(Attanasio et al., 2014). 91 of 140 (65%) differentially regulated genes showed direct binding by
Brg1 (Figure 3E), with positional enrichment at transcriptional start sites (TSSs) (Figure 3F,G).
Arid1b-mediated SWI/SNF transcriptional activities appeared to directly regulate numerous neuro-
psychiatric related genes, including ones implicated in ASD (Figure 3H,I). Our data also show that
haploinsufficiency is sufficient to cause broad gene expression disruption, but future studies will be
required to determine the exact downstream genes that account for the neuropsychiatric
phenotypes.
Arid1b+/- mice exhibited GHRH-GH-IGF1 axis defects
Having establishing that Arid1b haploinsufficient mice recapitulate salient aspects of human ARID1B-
opathies, we were particularly interested in identifying reversible pathological mechanisms and ther-
apeutic opportunities. Since we identified neuroanatomical and neural expression aberrations in
Arid1b+/- mice, we also asked if any non-neuropsychiatric syndromic features were potentially
related to neurodevelopmental abnormalities. As mentioned previously, Arid1b+/- mice developed
reduced nose-to-rump length and weight (Figure 4A,B). Arid1b+/- mice had disproportionally small
kidneys and hearts, but no other gross organ defects (Figure 4—figure supplement 1A). Profiling
using metabolic cages showed that Arid1b+/- mice had equivalent food intake and water consump-
tion (Figure 4—figure supplement 1B,C), suggesting that size differences were unlikely due to food
intake or energetic differences.
A critical factor that regulates both body size and brain development is Insulin-like growth factor
(IGF1). We found a significant reduction in plasma IGF1 levels in Arid1b+/- mice (Figure 4C), and
confirmed a reduction in Igf1 mRNA in the liver, which is a major source of IGF1 (Figure 4D). To dis-
cern if there was a hypothalamic, pituitary, peripheral, or combinatorial problem that led to IGF1
deficiency, we performed a series of endocrinologic tests. In the same cohorts of mice with IGF1
deficiency, fasting GH was not significantly different in Arid1b+/- mice (Figure 4E). In addition, there
were no significant Gh mRNA expression differences between WT and Arid1b+/- pituitary glands
despite differences in Arid1b mRNA levels (Figure 4F). We also confirmed that plasma GH was not
altered in younger 2 week old Arid1b+/- mice, an age where GH levels are more critical for growth
(Figure 4G). The combination of low IGF1 and normal GH levels pointed to a peripheral defect with-
out appropriate GH compensation from the pituitary gland.
Because GH was not elevated as would be expected if there was only a peripheral IGF1 produc-
ing defect, we asked if the Arid1b+/- pituitary was capable of making and secreting sufficient
amounts of GH in the context of GH stimulation testing. In multiple cohorts of Arid1b+/- mice, GH
levels were never significantly different at baseline and also increased normally at multiple time
points after stimulation with Growth hormone-releasing hormone (GHRH) (Figure 4H). This indicated
a normal ability for the pituitary to respond to exogenous GHRH. Next, we attempted to determine
if the hypothalamus was not producing enough Ghrh. We dissected the mediobasal hypothalamus
containing Ghrh expressing neurons to examine Ghrh expression. We found that Ghrh mRNA levels
were not significantly different (Figure 4I), indicating a lack of appropriate GHRH response to IGF1
deficiency, suggesting a central defect that contributed to growth impairment.
Figure 2 continued
Source data 1.
DOI: 10.7554/eLife.25730.010
Figure supplement 1. Arid1b+/- and Arid1b-/- brains have defects in cortical development.
DOI: 10.7554/eLife.25730.011
Figure supplement 1—source data 1.
DOI: 10.7554/eLife.25730.012
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In addition, we sought genetic evidence for a partial central (hypothalamic or pituitary) root cause
of IGF1 deficiency by generating organ-specific Arid1b mutant models. We used Nestin-Cre in the
brain, Albumin-Cre in the liver, and Ckmm-Cre in the skeletal muscles to spatially control Arid1b
haploinsufficiency. Neither Albumin-Cre; Arid1bFl/+ (Figure 4J) nor Ckmm-Cre; Arid1bFl/+ mice (data
not shown) showed growth or morphological defects, while Nestin-Cre; Arid1bFl/+ mice recapitu-
lated the growth impairments seen in whole body Arid1b+/- mice (Figure 4K), suggesting at least a
neuronal contribution to growth impairment. While Albumin-Cre; Arid1bFl/+ mice showed no IGF1
differences, Nestin-Cre; Arid1bFl/+ mice had reduced plasma IGF1 levels (Figure 4L,M). Moreover,
Nestin-Cre; Arid1bFl/+ mice showed an inappropriate lack of GH increase in the face of this IGF1
deficiency (Figure 4N). Since liver specific Arid1b+/- mice did not replicate the whole body Arid1b+/-
mice, it is possible that a combination of central and multi-organ peripheral defects in the GHRH-
GH-IGF1 axis were required to fully recapitulate the growth impairment of whole body Arid1b+/-
mice.
GH therapy reversed growth retardation and muscle weakness
Given plasma IGF1 deficiency in Arid1b+/- cohorts, we first tested if IGF1 replacement could rescue
physical aspects of developmental delay and abnormal behavioral phenotypes. Neither body size
(Figure 5A) nor elevated plus maze abnormalities (Figure 5B) were rescued after treating WT and
Arid1b+/- cohorts with recombinant human IGF1 (rhIGF1). This was not surprising because it is known
that exogenous IGF1 is unstable and often does not efficiently reach target tissues responsible for
growth (Kletzl et al., 2017).
The fact that GH was not elevated in the context of low IGF1 suggested to us that there was not
adequate GH production or compensation. Thus, we asked if GH supplementation could rescue
some of the physical aspects of developmental delay. WT and Arid1b+/- cohorts were treated with
recombinant mouse GH (rmGH) (Figure 5C). After 40 days of treatment, Arid1b heterozygous mice
gained significantly more body weight and nose-to-rump length than did WT mice (Figure 5D,E),
demonstrating that exogenous GH supplementation was sufficient to rescue growth retardation in
Arid1b+/- mice. Given this selective efficacy for mutant mice, we asked if GH could potentially
improve muscle weakness often associated with CSS. We found that at baseline, Arid1b+/- mice also
had muscle weakness identified through grip strength testing. Replacement with GH was able to
selectively increase muscle strength in mutant mice (Figure 5F,G). Despite improvements in physical
manifestations, GH replacement was not able to reverse behavioral phenotypes such as anxiety, as
measured in the elevated plus maze (Figure 5H). This suggested that correcting the GHRH-GH-IGF1
axis was not sufficient to rescue neuropsychiatric manifestations, but was able to reverse growth
retardation mediated by Arid1b deficiency.
In an analysis of 60 ARID1B CSS patients, height was shown to be significantly reduced
(Santen et al., 2014). In addition, some non-syndromic patients with missense mutations in ARID1B
exhibited growth deficiency due to partial GH deficiency (Yu et al., 2015). We also obtained clinical
information from additional CSS patients, two with ARID1B mutations (from the www.arid1bgene.
com database) and one with a mutation in SMARCA4, which encodes another SWI/SNF component.
All three of these cases had deficiencies in the GH-IGF1 axis and clear beneficial responses to GH
replacement therapy (growth curves for the ARID1B patients are shown in Figure 5—figure
Figure 3 continued
high confidence, Category 2: strong candidate, Category 3: suggestive evidence, Category 4: minimal evidence, Category 5: Hypothesized (Basu et al.,
2009). (E) Pie chart showing that 91 of 140 (65%) differentially regulated genes in hippocampus are direct targets of Brg1, a core SWI/SNF complex
subunit. Brg1 target genes were identified using ChIP-Seq in mouse e11.5 forebrain (Attanasio et al., 2014). (F) Metaplot showing enrichment of Brg1
at the TSSs of genes regulated by Arid1b. (G) Heatmap showing Brg1 promoter binding in these genes. (H) Differential mRNA expression of
representative genes involved in neurodevelopment and ASD (Data from: SFARI database, updated September, 2016) (Basu et al., 2009). (I) Brg1
peaks suggesting direct binding of SWI/SNF at the promoters of ASD-related genes. Values represent mean ± SEM. Asterisks indicate significant
differences between indicated littermate genotypes, *p-value  0.05; **p-value  0.01; ***p-value  0.001; ****p-value  0.0001; ns, not significant.
Student’s t-test (two-tailed distribution, two-sample unequal variance) was used to calculate p-values unless otherwise indicated in the corresponding
figure legend.
DOI: 10.7554/eLife.25730.013
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Figure 4. Growth retardation in Arid1b+/- mice is due to GH-IGF1 axis deficiency with a neuronal source. (A) Body length (nose-to-rump) curve of
females (n = 9 WT and 9 Arid1b+/-). (B) Body weight growth curve for males (n = 14 WT and 14 Arid1b+/-) and females (n = 20 WT and 20 Arid1b+/-). For
(A) and (B), repeated ANOVA with Bonferroni’s post-hoc analysis was used. (C) Plasma IGF1 as measured by ELISA (n = 16 WT and 19 Arid1b+/- 28–41
day old male and female mice). (D) Igf1 mRNA in WT and Arid1b+/- livers as measured by qPCR (n = 5 WT and 5 Arid1b+/- livers from 45 day old female
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supplement 1A,B). These data from humans and mice suggest deficiencies at various parts of the
GHRH-GH-IGF axis, leading to growth impairment responsive to GH supplementation.
Discussion
In summary, we have developed the first mouse model of Arid1b haploinsufficiency, one of the most
common genetic lesions found in ASD, ID, and CSS. Several aspects of our model recapitulated the
features of the overlapping disorders associated with ARID1B (Table 1). Our model is faithful to the
heterozygosity seen in most ARID1B-opathies. It is interesting that another model of ASD involving a
chromatin remodeling gene called CHD8 also requires haploinsufficiency (Katayama et al., 2016)
and suggests that dose could play a critical mechanistic role in phenotypes resulting from mutations
in epigenetic regulators. Our study also raises interesting questions about how genotype relates to
phenotype in diseases involving ARID1B. Some children with ARID1B mutations have a subset but
not all features of CSS, and others have different disorders such as ASD or isolated corpus callosum
agenesis. For example, Yu et al. reported cases of idiopathic short stature without cognitive defects
that were attributed to de novo ARID1B missense mutations, suggesting that there are either differ-
ences between mutations or important genetic interactions that play a key role in defining the phe-
notypic expression of these mutations (Yu et al., 2015). It is also possible that differences between
the function of Arid1b in mouse and human brain development account for intellectual and cognitive
discrepancies. Our mouse model affords the ability to interrogate these types of questions in differ-
ent strain backgrounds and with genetic interactors. We are hopeful that this will advance the under-
standing of ARID1B and SWI/SNF in human diseases.
We also uncovered a role for the GHRH-GH-IGF1 axis in ARID1B-opathies. Previously, height was
shown to be reduced in ARID1B patients (Santen et al., 2014), but there are only anecdotal findings
of GH deficiencies (Figure 5—figure supplement 1A,B) (Yu et al., 2015). After the clinical identifi-
cation of ARID1B or SWI/SNF mutations, interventions for short stature are usually not investigated.
Thus, it is likely that GHRH-GH-IGF1 deficiency is under-diagnosed and rarely treated in this patient
population. Conversely, ARID1B mutations are not suspected in patients with non-syndromic short
stature, and could represent a more common causative mechanism than previously suspected. The
findings here should motivate deeper interrogation of the GHRH-GH-IGF1 axis and potentially GH
supplementation in syndromic patients with CSS or non-syndromic patients with ARID1B mutations
and short stature.
Our study does not pinpoint the exact source of the peripheral IGF1 deficiency since liver-specific
Cre lines did not recapitulate the IGF1 deficiency seen in the whole body Arid1b+/- mice. Given the
Nestin-Cre results, it is possible that reduced IGF1 production in the brain led to reduced plasma
Figure 4 continued
mice). (E) Plasma GH as measured by ELISA (n = 15 WT and 14 Arid1b+/- 28–41 day old male and female mice). (F) Gh mRNA in WT and Arid1b+/-
pituitary as measured by qPCR (n = 6 WT and 5 Arid1b+/- pituitary from 33-44 day old female mice). (G) Plasma GH (n = 9 WT and 9 Arid1b+/- 2 week
old male mice). (H) Plasma GH before and after stimulation by human GHRH (n = 19 WT and n = 20 Arid1b+/- mice at baseline, n = 11 WT and n = 10
Arid1b+/- mice 5 and 15 min after GHRH administration). (I) Ghrh mRNA in WT and Arid1b+/- mediobasal hypothalamus as measured by qPCR. (n = 8
WT and 7 Arid1b+/- samples from 33-44 day old female mice). (J) Body weight curve for female Arid1bFl/+ (n = 9) and Albumin-Cre; Arid1bFl/+ (n = 15)
mice. (K) Body weight curve for female Arid1bFl/+ (n = 10) and Nestin-Cre; Arid1bFl/+ (n = 6) mice. (L) Plasma IGF1 levels for 40–45 day old female
Arid1bFl/+ (n = 7) and Albumin-Cre; Arid1bFl/+ (n = 7) mice. (M) Plasma IGF1 levels for 30–45 days old female Arid1bFl/+ (n = 6) and Nestin-Cre;
Arid1bFl/+ (n = 6) mice. (N) Plasma GH levels for female Arid1bFl/+ (n = 5) and Nestin-Cre; Arid1bFl/+ (n = 5) mice. Values represent mean ± SEM.
Asterisks indicate significant differences between indicated littermate genotypes, *p-value  0.05; **p-value  0.01; ***p-value  0.001; ****p-
value  0.0001; ns, not significant. Student’s t-test (two-tailed distribution, two-sample unequal variance) was used to calculate p-values unless
otherwise indicated in the figure legend.
DOI: 10.7554/eLife.25730.014
The following source data and figure supplements are available for figure 4:
Source data 1.
DOI: 10.7554/eLife.25730.015
Figure supplement 1. Growth and metabolic analysis of Arid1b+/- mice.
DOI: 10.7554/eLife.25730.016
Figure supplement 1—source data 1.
DOI: 10.7554/eLife.25730.017
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IGF1 and the inability to compensate with GHRH and GH exacerbated growth retardation. Another
possibility that subtle peripheral defects in the liver and muscle will only manifest when combined
with defects in other organs such as the brain. Future studies with tissue-specific conditional experi-
ments could help to resolve these questions. Overall, our study provides a preclinical model for
mechanistic and therapeutic dissection of ARID1B related diseases, and offers a translatable avenue
to alleviate growth related aspects of developmental delay.
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Figure 5. GH therapy reverses growth retardation and muscle weakness. (A) Body weights at p50 (WT + vehicle (n = 12), WT + rhIGF1 (n = 12),
Arid1b+/- + vehicle (n = 13) and Arid1b+/- + rhIGF1 (n = 13)). (B) Time spent in the closed arms of elevated plus maze at p50 (WT + vehicle (n = 27), WT
+ rhIGF1 (n = 29), Arid1b+/- + vehicle (n = 21) and Arid1b+/- + rhIGF1 (n = 22)). For (A) and (B), 0.5 mg/kg rhIGF1 was administrated daily starting from
postnatal day 11. (C) Schema showing the duration and dose of daily recombinant GH treatment. (D) Body weights at p50 (WT + vehicle (n = 20), WT +
rmGH (n = 16), Arid1b+/- + vehicle (n = 16) and Arid1b+/- + rmGH (n = 16)). (E) Nose-to-rump lengths at p50 (WT + vehicle (n = 7), WT + rmGH (n = 7),
Arid1b+/- + vehicle (n = 6) and Arid1b+/- + rmGH (n = 6)). (F) Forelimb grip strength at p50 (WT + vehicle (n = 9), WT + rmGH (n = 9), Arid1b+/- +
vehicle (n = 9) and Arid1b+/- + rmGH (n = 9)). (G) Hindlimb grip strength at p50 (WT + vehicle (n = 9), WT + rmGH (n = 9), Arid1b+/- + vehicle (n = 9)
and Arid1b+/- + rmGH (n = 9)). (H) Time spent in the closed arms of elevated plus maze at p50 (WT + vehicle (n = 19), WT + rmGH (n = 16), Arid1b+/- +
vehicle (n = 19) and Arid1b+/- + rmGH (n = 16)). Values represent mean ± SEM. Asterisks indicate significant differences between indicated littermate
genotypes: *p-value  0.05; **p-value  0.01; ***p-value  0.001; ****p-value  0.0001; ns, not significant. Two-way ANOVA was used to calculate the
p-value.
DOI: 10.7554/eLife.25730.018
The following source data and figure supplement are available for figure 5:
Source data 1.
DOI: 10.7554/eLife.25730.019
Figure supplement 1. Two ARID1B mutant CSS patients were GH deficient and responsive to GH replacement.
DOI: 10.7554/eLife.25730.020
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Materials and methods
Mice
All animal procedures were based on animal care guidelines approved by the Institutional Animal
Care and Use Committee at University of Texas Southwestern Medical Center (UTSW). Constitutive
and conditional Arid1b knockout mice were generated by the UTSW Transgenic Core using CRISPR/
Cas9 genome editing. Guide RNAs were designed to target sequences before and after exon 5 of
Arid1b, creating a frame-shift mutation to induce nonsense-mediated decay. Guide RNAs, S. pyo-
genes Cas9 mRNA, and oligo donors containing LoxP sequences were injected into single celled
zygotes. C57BL/6J mice were used to generate these mice. To generate WT and Arid1b+/- study
mice, C57BL/6J WT females were crossed to Arid1b+/- males. Arid1b+/- mice were tail genotyped
using the primers CTTGGTCTTACCCATTTGCACAGT (forward) and GATGGAGGATCCTTAC
TACAGGGGGATT (reverse). Amplicon size for WT allele is 710 bp and deletion band is 310 bp.
Arid1b floxed mice were tail genotyped using the primers 5’-CTT GGT CTT ACC CAT TTG CAC
AGT-3’ (forward) and 5’-AGT GCC TAG GAA GGC AGA GTT TGA GAG-3’ (reverse). Amplicon size
for WT allele is 475 bp, and for floxed allele is 554 bp.
Pituitary and hypothalamus dissection
The whole pituitary and the mediobasal hypothalamus (MBH), which includes both the arcuate
nucleus (ARC) and the ventromedial (VMH) hypothalamus, were dissected and subjected to RT-
qPCR analysis.
RNA extraction and qRT-PCR
Total RNA was isolated using TRIzol reagent (Invitrogen (Carlsbad, California), catalog no.
15596018). cDNA synthesis was performed with 1 mg of total RNA using the iScript RT Supermix
(BioRad, catalog no. 1708840). SYBR Green based quantitative real-time PCR was performed. Gene
expression levels were measured using the DDCt method. Mouse Arid1b primers were: forward, 5’-
GTTGGCTCTCCTGTGGGAAGCAA-3’; reverse, 5’- GTGACTGGCTCAAGGCAGGAT-3’.
Western blot assay
Tissues were lysed in TPER tissue protein extraction reagent and homogenized in FastPrep tissue
homogenizer. Western blots were performed in standard fashion. Primary antibodies were prepared
in 5% BSA in PBS-T. The following primary antibody was used: Arid1b Antibody (KMN1) X (cat #: sc-
32762 X, RRID:AB_2060367). Following secondary antibody was used: anti-mouse IgG, HRP-linked
antibody (Cell Signaling, #7076, RRID:AB_330924).
Table 1. Major clinical features associated with ARID1B mutations and phenotypes seen in Arid1b+/- mice. Abbreviations: CSS: Coffin-
siris syndrome, ID: Intellectual disability, ASD: Autism spectrum disorder.
Human ARID1B features Diagnosis References Mouse
Intellectual/cognitive disability CSS, ID (Hoyer et al., 2012; Santen et al., 2012; Halgren et al., 2012) No
Growth retardation CSS (Tsurusaki et al., 2012) Yes
Coarse facial features CSS (Sim et al., 2015) Unknown
Muscle hypotonia CSS (Hoyer et al., 2012) Yes
Hydrocephalus CSS (Imai et al., 2001) Yes
Corpus callosum agenesis or hypoplasia CSS (Halgren et al., 2012; Santen et al., 2012) Yes
Brachydactyly, hypoplastic nail/finger CSS (Hoyer et al., 2012; Santen et al., 2012; Brautbar et al., 2009) Unknown
Abnormal vocalization, speech impairment ASD, CSS (Santen et al., 2012) Yes
Anxiety ASD, CSS (O’Roak et al., 2012; Deciphering Developmental Disorders Study, 2015) Yes
Social interaction deficits ASD (O’Roak et al., 2012; Deciphering Developmental Disorders Study, 2015) Yes
Repetitive behaviors ASD (O’Roak et al., 2012; Deciphering Developmental Disorders Study, 2015) Yes
DOI: 10.7554/eLife.25730.021
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Immunohistochemistry (IHC)
Perinatal mice were decapitated after anesthesia. Heads were fixed in 4% PFA overnight before
brains were extracted. Adult mice were anesthetized and underwent intracardial perfusion with ice-
cold 0.1 M phosphate-buffered saline (PBS) followed by 4% PFA for fixation. Extracted brains were
immersed for 24 hr in 4% PFA in 0.1M PBS at 4˚C for post-fixation, followed by least three days of
immersion in 30% sucrose in 0.1 M PBS with 0.01% sodium azide for cryoprotection. Brains were cut
into 40 mm- (adult) or 20 mm-thick (perinatal) sections with a cryostat (model CM3050S; Leica). Brain
sections were permeabilized with 0.25% Triton X-100 in 1PBS and then blocked for 2 hr with 5%
BSA/3% normal goat serum (NGS) in 0.25% Triton X-100 in 1PBS. Primary antibodies for TBR1
(1:150 dilution, rabbit, polyclonal, Abcam Cat# ab31940 RRID:AB_2200219) were applied to sections
overnight at 4˚C. To count cell number, brain sections were incubated with Hoechst 33342 (1 mg/ml;
Cell Signaling Technology Cat# 4082S RRID:AB_10626776) alone or together with secondary anti-
bodies (Alexa 488) for 2 hr at room temperature.
For the analysis of proliferation, adult mice received one BrdU injection for five consecutive days,
and three days following the last injection, brains were fixed and harvested. Slide-mounted IHC for
BrdU-, Ki67-, and doublecortin- immunoreactive (+) cells in dentate gyrus was performed as
described previously (DeCarolis et al., 2014; Walker et al., 2015). Briefly, every ninth section of the
hippocampus was slide-mounted onto charged slides and left for two hours to dry. Antigen retrieval
was performed using 0.01 M citric acid (pH 6.0) at 100˚C for 15 min, followed by washing in PBS at
room temperature (RT). Hydrogen peroxide (0.3% H2O2) incubation was performed for 30 min to
inhibit endogenous peroxidase activity. For BrdU IHC, permeabilization with 0.1% Trypsin in 0.1 M
TRIS and 0.1% CaCl2 and denaturation with 2N HCl in 1x PBS were performed in order to allow anti-
body access to nuclear DNA. One hour of blocking non-specific binding was performed by incuba-
tion in 3% donkey serum, 0.3% Triton-X in PBS. Following these steps, slides were incubated with
rat-a-BrdU (1:400; Bio-Rad / AbD Serotec Cat# OBT0030 RRID:AB_609568), rabbit-a-Ki67 antibody
(1:500; Thermo Fisher Scientific Cat# RM-9106-S0 RRID:AB_2341197) in 3% serum and 0.3% Tween-
20 overnight. Primary antibody incubation was followed by 1 x PBS rinses and a 1 hr incubation with
a biotin-tagged secondary antibody targeting the respective primary antibody. Following rinses with
1x PBS, incubation with an avidin-biotin complex occurred for 90 min. Incubation with diaminobenzi-
dine for 5–10 min was used to visualize immunoreactive cells. The counterstain Fast Red was used
for nuclear visualization (~3 min incubation). Lastly, slides were placed through an ethanol dehydra-
tion series and coverslipped with DPX.
Stereological cell counts
BrdU+ and Ki67+ cells were quantified using an Olympus BX-51 microscope at 40X by an observer
blind to experimental groups as previously described (Walker et al., 2015). Immunopositive cells
were quantified in every 9th coronal section in the subgranular zone of the granular cell layer in the
dentate gyrus, spanning the entire anterior-posterior axis of the hippocampus ( 0.82 mm to  4.78
mm from Bregma). Manual stereological counting was performed under bright field, and total cell
counts were multiplied by nine to account for the whole hippocampus. Doublecortin+ cells were
quantified using the Optical Fractionator method, and dentate gyrus and corpus callosum volume
were assessed using Cavalieri analysis. Stereoinvestigator was used to perform both of these techni-
ques. Investigators were blinded to genotypes during sectioning, counting, and analysis.
RNA-Seq and ChIP-Seq
RNA from four WT and four Arid1b+/- hippocampi from 78 to 82 day old females were purified with
a QIAGEN miRNeasy Mini Kit. NuGEN libraries were made with these RNAs. These indexed libraries
were multiplexed in a single flow cell lane and received 75 base single-end sequencing on a NextSeq
500 using the High Output Kit v2 (75 cycles) at the CRI Sequencing Facility. Raw sequencing reads
were trimmed to remove adaptor and low quality sequences (Phred score <20) using trim_galore
package (http://www.bioinformatics.babraham.ac.uk/projects/trim_galore/). Trimmed reads were
aligned to mouse reference genome GRCm38/mm10 with HiSAT2 Kim et al., 2015. After duplicates
removal by SAMtools (Li et al., 2009) and Picard (http://broadinstitute.github.io/picard.), read
counts were generated for the annotated genes based GENCODE V20 (Harrow et al., 2012) using
featureCounts (Liao et al., 2014). Differential gene analysis was performed use
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edgeR (Robinson et al., 2010), using FDR < 0.05 as cutoff. Enriched pathways were analyzed
through the use of QIAGEN’s Ingenuity Pathway Analysis (IPA, QIAGEN RedwoodCity, www.qiagen.
com/ingenuity). Heatmaps to visualize the data were generated by using GENE-E (www.broadinsti-
tute.org/cancer/software/GENE-E). RNA-Seq data is deposited to GEO database and can be
accessed through GEO accession number (GSE92238). Brg1 ChIP-seq data from the forebrain was
downloaded from GEO with the accession number GSM912547 in GSE37151. Files were remapped
to the mm10 genome build by CrossMap. Brg1 target genes were predicted by using BETA-minus
program on the Cistrome Analysis Pipeline, an integrative platform for transcriptional regulation
studies. Heatmap and Metaplot were generated using deeptools, a flexible platform for exploring
deep-sequencing data.
Metabolic cage studies
Metabolic cage studies were performed in a temperature-controlled room containing 36 TSE meta-
bolic cages (The TSE Labmaster System of Germany) maintained by UTSW Metabolic Core. Three
days prior to study, mice were introduced to metabolic cages and after three day acclimation, cages
were connected to TSE system and parameters were recorded for a total of five days. Investigators
were blinded to mouse genotypes.
Grip strength test
Muscle strength was measured by a grip strength test performed by the Neuro-Models Core Facility
at UT Southwestern Medical Center in a blinded fashion. Test was conducted using a wire mesh grid
connected to a horizontally-aligned force meter (San Diego Instruments, San Diego, CA). The grid
was secured at a 45 degree angle, and the top rung of the grid was used for all testing. Mice were
held at the base of the tail and supported ventrally while being moved into position to grasp the
wire grid. Once the rug was successfully grasped, mice were gently pulled in a horizontal plane until
the animal’s grip was released from the grid. Peak force (in gram-force units, gf) was captured by
the force meter and recorded for later analysis. Forelimb and hindlimb tests were conducted sepa-
rately, with each being measured five times over a 2–3 min period. Investigators were blinded to
mouse genotypes and the identity of treatment groups. Arid1b+/- mice with apparent hydrocephaly
were excluded. Experiment was performed once.
Ultrasonic vocalization recordings
Ultrasonic vocalizations (USVs) were recorded from both male and female pups isolated from their
mothers at P4, during the daylight period of the light/dark cycle. Dams and their litters were accli-
mated for 30 min in the test room. Each pup was removed from the cage containing its mother and
littermates and placed in a clean plastic container in a wooden sound-attenuating recording cham-
ber. Each pup was first acclimated in the recording chamber for 30 s then recorded for 10 min.
Recordings were acquired using an UltraSoundGate CM16/CMPA condenser microphone (Avisoft
Bioacoustics) positioned at a fixed height of 8 cm above the pups, and were amplified and digitized
(sampled at 16 bits, 250 kHz) using UltraSoundGate 416 hr 1.1 hardware and Avisoft-RECORDER
software (Avisoft Bioacoustics). The data were transferred to Avisoft-SASLab Pro (version 5.2) to ana-
lyze spectrograms of vocalizations with settings of 0% overlapping FlatTop windows, 100% frame
size, and 256 points fast Fourier transform (FFT) length. The following measures were recorded for
each group: number of USV calls, mean duration of USV calls, and mean peak frequency. Recordings
were performed with the experimenter blinded to mouse genotypes.
Juvenile social interaction test
The adult male test mouse was placed into a fresh home cage and habituated in the test room with
red light for 15 min before testing. A three week old male juvenile mouse was placed into the oppo-
site end of the cage that the test mouse was already in. Active interactions between the mice were
scored manually with 2 min of total test time. Only interactions when the test mouse is interacting
with the juvenile, but not other way around were scored. Non-strict male littermates were used.
Arid1b+/- mice with obvious hydrocephaly were excluded. The experiment was performed twice.
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Grooming test
The test was performed between 10:00 am and 2:00 pm. Adult female mouse was singly placed into
a new standard cage, without nestlets, food, or water, acclimated for 10 min, then videotaped for
another 10 min. The amount of time spent grooming was recorded continuously to calculate the
total time spent grooming. Grooming is considered self-grooming of any part of the body (including
the face, head, ears, full-body). Data is plotted as percent of total time spent grooming.
Marble burying test
The test mouse was acclimated for 30 min in the testing room. One standard housing cage for each
test mouse was filled with clean bedding material. 15 clean marbles were arranged on top of the
bedding in each cage, forming five even rows and three columns. Mice were placed individually into
the prepared cages and kept undisturbed for 30 min. After the testing period, they were returned
to their original cages. A still image of the test cage was taken to record the number and pattern of
buried marbles. A marble was considered buried if more than 2/3 of its depth is covered. Results
were calculated and plotted as the percentage of marbles buried per genotype.
Locomotor activity
This test was performed by UTSW Rodent Core Facilty. Experimenters were blinded to mouse geno-
types. The experiment was repeated two times and combined data is included. Mice were placed
individually into a clean, plastic mouse cage (18 cm x 28 cm) with minimal bedding. Each cage was
placed into a dark Plexiglas box. Movement was monitored by 5 photobeams in one dimension
(Photobeam Activity System, San Diego Instruments, San Diego, CA) for 2 hr, with the number of
beam breaks recorded every 5 min. The movement is characterized in three ways: repetitive beam
breaks of a single beam is classified as stereotypy, consecutive beam breaks of two or more beams
is classified as ambulatory movements, and total beam breaks during each 5 min interval. Number of
total beam breaks during 5 min interval was reported. Arid1b+/- mice with apparent hydrocephaly
were excluded.
Open field activity test
The test was performed by UTSW Rodent Core Facilty. Experimenters were blinded to mouse geno-
types. Experiment was repeated two times and combined data is included. Mice were placed in the
periphery of a novel open field environment (44 cm x 44 cm, walls 30 cm high) in a dimly lit room
and allowed to explore for 5 min. The animals were monitored from above by a video camera con-
nected to a computer running video tracking software (Ethovision 3.0, Noldus, Leesburg, Virginia) to
determine the time, distance moved and number of entries into three areas: the periphery (5 cm
from the walls), the center (14 cm x 14 cm) and non-periphery (area excluding periphery). The open
field arenas were wiped and allowed to dry between mice. Locomotor activity test was performed
prior to open field activity test in these cohorts. Arid1b+/- mice with apparent hydrocephaly were
excluded.
Elevated plus maze
Test was performed by UTSW Rodent Core Facilty. Experimenters were blinded to mouse geno-
types. Experiment was repeated two times and combined data is included. Mice were placed in the
center of a black Plexiglas elevated plus maze (each arm 30 cm long and 5 cm wide with two oppo-
site arms closed by 25 cm high walls) elevated 31 cm in a dimly lit room and allowed to explore for 5
min. The animals were monitored from above by a video camera connected to a computer running
video tracking software (Ethovision 3.0, Noldus, Leesburg, Virginia) to determine time spent in the
open and closed arms, time spent in the middle, and the number of entries into the open and closed
arm. The apparatus was wiped and allowed to dry between mice. Locomotor activity and open field
activity test were performed prior to elevated plus maze in these cohorts. Arid1b+/- mice with appar-
ent hydrocephaly were excluded.
Dark-Light activity
Test was performed by UTSW Rodent Core Facilty. Experimenters were blinded to mouse geno-
types. Experiment was repeated two times and combined data is included. Mice were placed into a
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black Plexiglas chamber (25 cm x 26 cm) and allowed to explore for 2 min. After the habituation
period, a small door was opened allowing them to access the light side of the apparatus (25 cm x 26
cm lit to approximately 1700 lux) for 10 min. The animals were monitored by 7 photobeams in the
dark compartment and 8 photobeams on the light side connected to a computer which recorded
the time spent in each compartment, latency to enter the light side and the number of entrances to
each compartment (Med-PC IV, Med Associates, St. Albans, VT). The dark-light apparatus was wiped
and allowed to dry between mice. Locomotor activity, open field activity, and elevated plus maze
tests were performed prior to dark-light activity test in these cohorts. Arid1b+/- mice with apparent
hydrocephaly were excluded.
Morris water maze
Test was performed by UTSW Rodent Core Facilty. Experimenters were blinded to mouse geno-
types. A circular pool was filled with room temperature water to a depth of approximately 12 inches.
A platform (10 cm diameter) was placed in one quadrant of the pool with the top of the platform
about 2 cm below the water level. White non-toxic paint was added to enhance the contrast with
the animal and to hide the location of the platform. Each day the mice were placed in the pool and
allowed to swim for 1 min to find the platform. The swim path and time until locating the platform
wasrecorded via a videocamera and computer running videotracking software (Ethovision, Noldus).
If the mouse does not find the platform within a minute, they were gently guided or placed on the
platform for 10 s, then removed from the pool and return to their home cage. Each animal was
placed in the pool for a total of four times each day for 13 days. Twenty-four hours after the last
training day, a probe test was conducted in which the platform was removed from the pool and
each mouse was allowed to swim for 1 min to determine whether the animal has learned the location
of the platform. The time each animal spends in the quadrant which had contained the platform on
training days and the number of times that the animal crosses the location which had contained the
platform are indicators of how well the animal has learned the spatial location of the platform. To
control for visual problems, the mice weregiven 4–6 trials after the probe test using the same pool
and platform, however a large black block was placed on top of the platform to clearly mark the
location. The location of the platform was moved on each trial.
Fear conditioning
Test was performed by UTSW Rodent Core Facilty. Experimenters were blinded to mouse geno-
types. Fear conditioning was measured in boxes equipped with a metal grid floor connected to a
scrambled shock generator (Med Associates Inc., St. Albans). For training, mice were individually
placed in the chamber. After 2 min, the mice received three tone-shock pairings (30 s white noise,
80 dB tone co-terminated with a 2 s, 0.5 mA footshock, 1 min intertrial interval). The following day,
memory of the context was measured by placing the mice into the same chambers and freezing was
measured automatically by the Med Associates software. Forty-eight hours after training, memory
for the white noise cue was measured by placing the mice in a box with altered floors and walls, dif-
ferent lighting, and a vanilla smell. Freezing was measured for 3 min, then the noise cue was turned
on for an additional 3 min and freezing was measured.
Footshock sensitivity
Test was performed by the UTSW Rodent Core Facility. Experimenters were blinded to mouse geno-
types. The mice were placed individually into boxes equipped with a metal grid floor connected to a
scrambled shock generator (Med Associates Inc., St. Albans). After approximately 1 min, the mice
received a series of footshocks (2 s each) with increasing intensity. The initial shock intensity was
0.05 mA and the amplitude was increased by 0.05 mA for each consecutive footshock with 15 s
intershock interval. The first shock intensity that each animal displayed each behaviour (flinch, jump,
and vocalization) was recorded. Once the animal displayed all three behaviours, it was removed
from the chamber.
GH stimulation test and ELISA experiments
Plasma IGF-1 concentration was determined using mouse/rat IGF-1 Quantikine ELISA Kit (R and D
Biosystems, Cat #: MG100) without fasting. Mice were fasted for 36 hr before GH stimulation
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testing. Fifteen minutes after anesthesia with pentobarbital (50 mg/kg given once i.p.), 0.14 g/kg
GHRH (Phoenix Pharmaceuticals, Cat #:031–02) was injected i.p. Blood was sampled retro-orbitally
using a capillary tube before, 5, and 15 min after injection. Plasma GH concentration was measured
using a Rat/Mouse GH ELISA KIT (Millipore, Cat #: EZRMGH-45K).
Recombinant human IGF1 (rhIGF1) therapy
See Figure 5C. Mice at the age of P10 were ranked from highest to lowest body weight and even
numbered mice were placed into the treatment group and odd numbered mice were placed into
the vehicle group. Arid1b+/- mice with apparent hydrocephaly were excluded. Recombinant human
IGF1 was purchased from Peprotech (Catalog:#100–11). It was prepared according to datasheet and
injected intraperitoneally. Vehicle or 0.5 mg/kg rhIGF1 dissolved in vehicle were injected starting
from P11 daily.
Recombinant mouse growth hormone (rmGH) therapy
Mice at the age of P11 were ranked from highest to lowest body weight and even numbered mice
were placed into the treatment group and odd numbered mice were placed into the vehicle group.
Arid1b+/- mice with apparent hydrocephaly were excluded. Recombinant mouse growth hormone
was obtained from National Hormone and Peptide Program (NHPP). It was prepared according to
the NHPP datasheet. Injection was performed subcutaneously. 30 ug GH/mouse/day was injected
between P11 to P14, 50 ug GH/mouse/day was injected between P14 to P21, 70 ug GH/mouse/day
was injected between P21 to P50. Grip strength test was performed at P60 after 10 days without
treatment.
Statistical analyses
Unless specified otherwise in the figure legends, statistical analyses were performed using unpaired,
two-tailed, Student’s t-test or ANOVA. The data bars and error bars indicate mean ± standard error
mean (SEM). *p-value  0.05; **p-value  0.01; ***p-value  0.001; ****p-value  0.0001; ns, not
significant. No statistical methods were used to predetermine sample sizes; however, sample sizes
were estimated based on similar experiments reported in the relevant literature in the field
(Araujo et al., 2015 and Katayama et al., 2016).
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